Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Predicts Future Risk of Cardiovascular Events Independently of Established Risk Factors

2016226 citationsJournal Articlebronze Open Access

Authors

Karin Leander · Pfizer (Sweden)

Anders Mälarstig · Eli Lilly (United States)

Ferdinand M. van’t Hooft · Pfizer (Sweden)

Craig Hyde · Pfizer (Sweden)

Mai-Lis Hellénius · Eli Lilly (United States)

Jason S. Troutt · Eli Lilly (United States)

Robert J. Konrad ·

Abstract

Serum PCSK9 concentration is associated with future risk of CVD even after adjustments for established CVD risk factors. Further studies are needed to confirm this observation.

Topics & Keywords

Lipoproteins and Cardiovascular Health Pharmaceutical Economics and Policy

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Circulation

Volume 133, Issue 13, pp. 1230-1239

DOI: 10.1161/circulationaha.115.018531

Field-Weighted Citation Impact: 24.79